On October 21, 2015 Admune Therapeutics reported that it has agreed to the sale of Admune to Novartis (Press release, Admune, OCT 21, 2015, View Source [SID:1234507779]). The focus of the acquisition is Admune’s lead compound, Heterodimeric IL-15 (IL15:IL15Ra), a novel IL-15 agonist that may have broad applications for cancer immunotherapy. Admune will be integrated into Novartis’ rapidly expanding immune-oncology portfolio.
Admune’s IL-15 agonist is currently in phase I clinical trials for metastatic cancers at the National Cancer Institute of the National Institutes of Health. In pre-clinical studies, IL-15 therapies have been shown to activate lymphocyte cells including CD8+ T-cells and Natural Killer (NK) cells that play a critical role in stimulating the body’s immune system.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!